The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     
 


Published online October 28, 2009
The Journal of Immunology, 2009, doi:10.4049/jimmunol.0901474
Copyright © 2009 by The American Association of Immunologists, Inc.

This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jimmunol.0901474v1
183/10/6186    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Didierlaurent, A. M.
Right arrow Articles by Garçon, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Didierlaurent, A. M.
Right arrow Articles by Garçon, N.

AS04, an Aluminum Salt- and TLR-4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity1

Arnaud M. Didierlaurent,23* Sandra Morel,2* Laurence Lockman,* Sandra L. Giannini,* Michel Bisteau,* Harald Carlsen,{dagger} Anders Kielland,{dagger} Olivier Vosters,4{ddagger} Nathalie Vanderheyde,* Francesca Schiavetti,5* Daniel Larocque,§ Marcelle Van Mechelen,* and Nathalie Garçon*

*GlaxoSmithKline Biologicals, Rixensart, Belgium; {dagger}Cgene, Oslo, Norway; {ddagger}Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium; and §GlaxoSmithKline Biologicals, Laval, Canada

Adjuvant System 04 (AS04) combines the TLR4 agonist MPL (3-O-desacyl-4'-monophosphoryl lipid A) and aluminum salt. It is a new generation TLR-based adjuvant licensed for use in human vaccines. One of these vaccines, the human papillomavirus (HPV) vaccine Cervarix, is used in this study to elucidate the mechanism of action of AS04 in human cells and in mice. The adjuvant activity of AS04 was found to be strictly dependent on AS04 and the HPV Ags being injected at the same i.m. site within 24 h of each other. During this period, AS04 transiently induced local NF-{kappa}B activity and cytokine production. This led to an increased number of activated Ag-loaded dendritic cells and monocytes in the lymph node draining the injection site, which further increased the activation of Ag-specific T cells. AS04 was also found to directly stimulate those APCs in vitro but not directly stimulate CD4+ T or B lymphocytes. These AS04-induced innate responses were primarily due to MPL. Aluminum salt appeared not to synergize with or inhibit MPL, but rather it prolonged the cytokine responses to MPL at the injection site. Altogether these results support a model in which the addition of MPL to aluminum salt enhances the vaccine response by rapidly triggering a local cytokine response leading to an optimal activation of APCs. The transient and confined nature of these responses provides further supporting evidence for the favorable safety profile of AS04 adjuvanted vaccines.

3 Address correspondence and reprint requests to Dr. Arnaud Didierlaurent, GlaxoSmithKline Biologicals, Rue de l'Institut 98, 1330 Rixensart, Belgium. E-mail address: arnaud.didierlaurent{at}gskbio.com

1 This work was supported by GlaxoSmithKline Biologicals (to H.C. and A.K.).

2 A.D. and S.M. contributed equally to this work.

4 Current address: Institut de Recherche Interdisciplinaire en Biologie Humaine et Moléculaire, Université Libre de Bruxelles, Brussels, Belgium.

5 Current address: Novartis Vaccines, Sienna, Italy.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
This Website Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2009 by The American Association of Immunologists, Inc. All rights reserved.